Shopping Cart 0
Cart Subtotal
USD 0

Autism - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Autism-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review, H2 2018, provides an overview of the Autism (Central Nervous System) pipeline landscape.

Autism, also known as complex developmental disability, is a neurodevelopment disorder characterized by social interaction, verbal and nonverbal communication and repetitive behaviors. Risk factors include child's sex, family history, fragile X syndrome, Tourette syndrome and epilepsy. Treatment includes SSRIs (selective serotonin reuptake inhibitors), antidepressants, antipsychotics, and sedatives.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Autism-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Autism (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Autism (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Autism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 3, 21, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Autism (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Autism (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Autism (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Autism (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Autism (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Autism (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Autism (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Autism (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 4

Tourette Syndrome-Overview 5

Tourette Syndrome-Therapeutics Development 6

Tourette Syndrome-Therapeutics Assessment 11

Tourette Syndrome-Companies Involved in Therapeutics Development 18

Tourette Syndrome-Drug Profiles 22

Tourette Syndrome-Dormant Projects 64

Tourette Syndrome-Discontinued Products 65

Tourette Syndrome-Product Development Milestones 66

Appendix 76


List Of Figure

List of Figures

Number of Products under Development for Autism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Autism, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Autism-Pipeline by 4D Pharma PLC, H2 2018

Autism-Pipeline by AgeneBio Inc, H2 2018

Autism-Pipeline by APeT Holding BV, H2 2018

Autism-Pipeline by Bantam Pharmaceutical LLC, H2 2018

Autism-Pipeline by BioHealthonomics Inc, H2 2018

Autism-Pipeline by BrainStorm Cell Therapeutics Inc, H2 2018

Autism-Pipeline by Coronis NeuroSciences Ltd, H2 2018

Autism-Pipeline by Curemark LLC, H2 2018

Autism-Pipeline by Evgen Pharma Plc, H2 2018

Autism-Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Autism-Pipeline by GW Pharmaceuticals Plc, H2 2018

Autism-Pipeline by Heptares Therapeutics Ltd, H2 2018

Autism-Pipeline by Immuron Ltd, H2 2018

Autism-Pipeline by Intra-Cellular Therapies Inc, H2 2018

Autism-Pipeline by Leading BioSciences Inc, H2 2018

Autism-Pipeline by MedDay SA, H2 2018

Autism-Pipeline by Omeros Corp, H2 2018

Autism-Pipeline by OptiNose US Inc, H2 2018

Autism-Pipeline by Ovensa Inc, H2 2018

Autism-Pipeline by RespireRx Pharmaceuticals Inc, H2 2018

Autism-Pipeline by Reviva Pharmaceuticals Inc, H2 2018

Autism-Pipeline by Sumitomo Chemical Co Ltd, H2 2018

Autism-Dormant Projects, H2 2018

Autism-Dormant Projects, H2 2018 (Contd..1), H2 2018

Autism-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Autism Therapeutic Products under Development, Key Players in Autism Therapeutics, Autism Pipeline Overview, Autism Pipeline, Autism Pipeline Assessment


Companies

4D Pharma PLC

AgeneBio Inc

APeT Holding BV

Bantam Pharmaceutical LLC

BioHealthonomics Inc

BrainStorm Cell Therapeutics Inc

Coronis NeuroSciences Ltd

Curemark LLC

Evgen Pharma Plc

F. Hoffmann-La Roche Ltd

GW Pharmaceuticals Plc

Heptares Therapeutics Ltd

Immuron Ltd

Intra-Cellular Therapies Inc

Leading BioSciences Inc

MedDay SA

Omeros Corp

OptiNose US Inc

Ovensa Inc

RespireRx Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Sumitomo Chemical Co Ltd